RepliCel Life Sciences Inc. (REPCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 287.78 Thousand CAD | -63.95% |
| 2022 | 798.21 Thousand CAD | 34.88% |
| 2021 | 591.79 Thousand CAD | 40.58% |
| 2020 | 420.96 Thousand CAD | -16.72% |
| 2019 | 505.46 Thousand CAD | -84.34% |
| 2018 | 3.22 Million CAD | 281.48% |
| 2017 | 846.02 Thousand CAD | -53.72% |
| 2016 | 1.82 Million CAD | 339.55% |
| 2015 | 415.92 Thousand CAD | -80.58% |
| 2014 | 2.14 Million CAD | 4.33% |
| 2013 | 2.05 Million CAD | 306.02% |
| 2012 | 505.48 Thousand CAD | -19.94% |
| 2011 | 631.41 Thousand CAD | -51.75% |
| 2010 | 1.3 Million CAD | 1335.91% |
| 2009 | 91.14 Thousand CAD | 59.7% |
| 2008 | 57.07 Thousand CAD | 59.06% |
| 2007 | 35.88 Thousand CAD | -88.32% |
| 2006 | 307.28 Thousand CAD | -90.53% |
| 2005 | 3.24 Million CAD | -5.49% |
| 2004 | 3.43 Million CAD | 19427.92% |
| 2003 | 17.59 Thousand CAD | -34.72% |
| 2002 | 26.94 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 202.52 Thousand CAD | -29.63% |
| 2024 Q2 | 172.67 Thousand CAD | -14.74% |
| 2023 FY | 287.78 Thousand CAD | -63.95% |
| 2023 Q4 | 287.78 Thousand CAD | -13.18% |
| 2023 Q3 | 331.46 Thousand CAD | -33.13% |
| 2023 Q2 | 495.64 Thousand CAD | -54.29% |
| 2023 Q1 | 1.08 Million CAD | 35.86% |
| 2022 FY | 798.21 Thousand CAD | 34.88% |
| 2022 Q2 | 574.89 Thousand CAD | 21.91% |
| 2022 Q1 | 471.56 Thousand CAD | -20.32% |
| 2022 Q3 | 456.61 Thousand CAD | -20.57% |
| 2022 Q4 | 798.21 Thousand USD | 74.81% |
| 2021 FY | 591.79 Thousand CAD | 40.58% |
| 2021 Q4 | 591.79 Thousand CAD | -11.06% |
| 2021 Q3 | 665.42 Thousand CAD | 1.62% |
| 2021 Q1 | 882.88 Thousand CAD | 109.73% |
| 2021 Q2 | 654.81 Thousand CAD | -25.83% |
| 2020 Q4 | 420.96 Thousand CAD | 7.31% |
| 2020 Q2 | 422.86 Thousand CAD | 57.52% |
| 2020 Q3 | 392.29 Thousand CAD | -7.23% |
| 2020 FY | 420.96 Thousand CAD | -16.72% |
| 2020 Q1 | 268.44 Thousand CAD | -35.95% |
| 2019 Q3 | 807.79 Thousand CAD | -5.86% |
| 2019 Q4 | 419.1 Thousand CAD | -48.12% |
| 2019 FY | 505.46 Thousand CAD | -84.34% |
| 2019 Q2 | 858.11 Thousand CAD | -53.89% |
| 2019 Q1 | 1.86 Million CAD | -42.34% |
| 2018 FY | 3.22 Million CAD | 281.48% |
| 2018 Q1 | 439.04 Thousand CAD | -48.1% |
| 2018 Q2 | 252.87 Thousand CAD | -42.4% |
| 2018 Q3 | 117 Thousand CAD | -53.73% |
| 2018 Q4 | 3.22 Million CAD | 2658.32% |
| 2017 Q3 | 452 Thousand CAD | -56.81% |
| 2017 Q1 | 3.5 Million CAD | 91.56% |
| 2017 FY | 846.02 Thousand CAD | -53.72% |
| 2017 Q4 | 846.02 Thousand CAD | 87.17% |
| 2017 Q2 | 1.04 Million CAD | -70.12% |
| 2016 Q2 | 327.56 Thousand CAD | -49.65% |
| 2016 Q4 | 1.82 Million CAD | 865.12% |
| 2016 Q3 | 189.42 Thousand CAD | -42.17% |
| 2016 FY | 1.82 Million CAD | 339.55% |
| 2016 Q1 | 650.53 Thousand CAD | 56.41% |
| 2015 Q2 | 1.98 Million CAD | 67.92% |
| 2015 FY | 415.92 Thousand CAD | -80.58% |
| 2015 Q3 | 756.22 Thousand CAD | -61.98% |
| 2015 Q4 | 415.92 Thousand CAD | -45.0% |
| 2015 Q1 | 1.18 Million CAD | -44.68% |
| 2014 Q2 | 4.44 Million CAD | 202.05% |
| 2014 Q4 | 2.14 Million CAD | -37.02% |
| 2014 Q1 | 1.47 Million CAD | -28.23% |
| 2014 FY | 2.14 Million CAD | 4.33% |
| 2014 Q3 | 3.4 Million CAD | -23.58% |
| 2013 Q2 | 218.55 Thousand CAD | -67.91% |
| 2013 FY | 2.05 Million CAD | 306.02% |
| 2013 Q4 | 2.05 Million CAD | -37.19% |
| 2013 Q3 | 3.26 Million CAD | 1395.02% |
| 2013 Q1 | 680.97 Thousand CAD | 34.72% |
| 2012 Q2 | 1.67 Million CAD | -1.06% |
| 2012 FY | 505.48 Thousand CAD | -19.94% |
| 2012 Q3 | 1.08 Million CAD | -35.62% |
| 2012 Q4 | 505.48 Thousand CAD | -53.23% |
| 2012 Q1 | 1.69 Million CAD | 168.73% |
| 2011 Q3 | 1.28 Million CAD | -36.26% |
| 2011 Q4 | 631.41 Thousand CAD | -51.03% |
| 2011 Q2 | 2.02 Million CAD | -29.17% |
| 2011 FY | 631.41 Thousand CAD | -51.75% |
| 2011 Q1 | 2.85 Million CAD | 118.24% |
| 2010 Q2 | 134.09 Thousand CAD | 101.11% |
| 2010 Q3 | 434.62 Thousand CAD | 224.13% |
| 2010 Q4 | 1.3 Million CAD | 201.12% |
| 2010 FY | 1.3 Million CAD | 1335.91% |
| 2010 Q1 | 66.67 Thousand CAD | -26.85% |
| 2009 Q1 | 38.83 Thousand CAD | -31.95% |
| 2009 Q4 | 91.14 Thousand CAD | -18.5% |
| 2009 Q3 | 111.83 Thousand CAD | -16.74% |
| 2009 Q2 | 134.31 Thousand CAD | 245.85% |
| 2009 FY | 91.14 Thousand CAD | 59.7% |
| 2008 Q2 | 34.36 Thousand CAD | -42.65% |
| 2008 Q4 | 57.07 Thousand CAD | 48.64% |
| 2008 Q3 | 38.39 Thousand CAD | 11.72% |
| 2008 Q1 | 59.92 Thousand CAD | 67.0% |
| 2008 FY | 57.07 Thousand CAD | 59.06% |
| 2007 Q3 | 39.87 Thousand CAD | 7.77% |
| 2007 FY | 35.88 Thousand CAD | -88.32% |
| 2007 Q1 | 92.33 Thousand CAD | -69.95% |
| 2007 Q2 | 36.99 Thousand CAD | -59.93% |
| 2007 Q4 | 35.88 Thousand CAD | -10.01% |
| 2006 Q4 | 307.28 Thousand CAD | -33.06% |
| 2006 Q1 | 3.47 Million CAD | 6.91% |
| 2006 FY | 307.28 Thousand CAD | -90.53% |
| 2006 Q2 | 549.88 Thousand CAD | -84.16% |
| 2006 Q3 | 459.05 Thousand CAD | -16.52% |
| 2005 Q4 | 3.24 Million CAD | -0.5% |
| 2005 FY | 3.24 Million CAD | -5.49% |
| 2005 Q1 | 3.38 Million CAD | -1.35% |
| 2005 Q2 | 3.39 Million CAD | 0.11% |
| 2005 Q3 | 3.26 Million CAD | -3.81% |
| 2004 Q3 | 4.69 Million CAD | 34.92% |
| 2004 Q1 | 16.19 Thousand CAD | 0.0% |
| 2004 Q2 | 3.47 Million CAD | 21371.24% |
| 2004 Q4 | 3.43 Million CAD | -26.77% |
| 2004 FY | 3.43 Million CAD | 19427.92% |
| 2003 FY | 17.59 Thousand CAD | -34.72% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | 26.94 Thousand USD | 0.0% |
| 2002 Q4 | 26.94 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.259% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 96.014% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.732% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 97.273% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.779% |
| Mesoblast Limited | 667.9 Million USD | 99.957% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -297.687% |
| Genus plc | 1.02 Billion USD | 99.972% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 78.814% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 42.332% |
| Marizyme, Inc. | 22.01 Million USD | 98.693% |
| ContraFect Corporation | 20.67 Million USD | 98.608% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 54.101% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 26.278% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 24.698% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 79.904% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 93.059% |
| MultiCell Technologies, Inc. | 126.22 USD | -227903.486% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 69.374% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.776% |
| EV Biologics, Inc. | 431.71 Thousand USD | 33.339% |
| Q BioMed Inc. | 3.51 Million USD | 91.814% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.182% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 62.656% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -10.146% |
| Biomind Labs Inc. | 73.81 Thousand USD | -289.854% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.938% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.041% |
| Skye Bioscience, Inc. | 11.94 Million USD | 97.59% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 91.313% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 89.521% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 85.303% |
| IMV Inc. | 31.33 Million USD | 99.082% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 58.139% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 88.945% |
| GB Sciences, Inc. | 103.44 Thousand USD | -178.21% |
| Alpha Cognition Inc. | 2.45 Million USD | 88.264% |
| HST Global, Inc. | 1526.00 USD | -18758.847% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Halberd Corporation | 10.13 Thousand USD | -2740.648% |
| Enzolytics Inc. | 361.7 Million USD | 99.92% |
| Resverlogix Corp. | 8.11 Million USD | 96.454% |
| Affymax, Inc. | 7.44 Million USD | 96.133% |
| SYBLEU INC | 330.46 Thousand USD | 12.916% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 84.675% |
| argenx SE | 4.54 Billion USD | 99.994% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.97% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.397% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1163.272% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 96.784% |
| AVAX Technologies, Inc. | 7.37 Million USD | 96.099% |
| Zenith Capital Corp. | 7410.00 USD | -3783.752% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.992% |
| Ember Therapeutics, Inc. | 184.00 USD | -156305.435% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 10.572% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -10.109% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.936% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 80.137% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 90.487% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.454% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 68.987% |
| BioStem Technologies, Inc. | 14.56 Million USD | 98.023% |
| ONE Bio Corp. | 70.08 Million USD | 99.589% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -404.056% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -12358.268% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 70.871% |
| Agentix Corp. | 261.39 Thousand USD | -10.097% |
| LadRx Corporation | 2.3 Million USD | 87.53% |
| Cell Source, Inc. | 195.17 Thousand USD | -47.453% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 40.114% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 18.616% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 18.616% |
| NovAccess Global Inc. | 62.24 Thousand USD | -362.322% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 55.009% |
| Itoco Inc. | 1.4 Million USD | 79.445% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -200.852% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -171.496% |
| Kadimastem Ltd | 2.3 Million USD | 87.51% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -276.91% |
| CytoDyn Inc. | 11.13 Million USD | 97.416% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -101.288% |
| Mobile Lads Corp. | 52.00 USD | -553334.615% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1509.541% |
| Qrons Inc. | 420.00 USD | -68420.476% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 25.342% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 47.876% |
| Rebus Holdings, Inc. | 5000.00 USD | -5655.72% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 29.709% |
| International Stem Cell Corporation | 5.39 Million USD | 94.661% |
| Bioxytran, Inc. | 137.63 Thousand USD | -109.089% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 98.082% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.264% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -264.286% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 66.718% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 96.172% |
| Neutra Corp. | 2851.00 USD | -9994.213% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.112% |
| PureTech Health plc | 693.97 Million USD | 99.959% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 96.434% |
| IXICO plc | 15.84 Million USD | 98.184% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 96.525% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.721% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.914% |